Impact of heteroresistance on treatment outcomes of people with drug-resistant TB
R Crowder,M Kato-Maeda,B Schwem,A Dela Tonga,D M Geocaniga-Gaviola,E Lopez,C L Valdez,A R Lim,N Hunat,A G Sedusta,C A Sacopon,G A M Atienza,E Bulag,D Lim,J Bascuña,K Shah,R P Basillio,C A Berger,M C D P Lopez,S Sen,C Allender,M Folkerts,U Karaoz,E Brodie,S Mitarai,A M C Garfin,M C Ama,D M Engelthaler,A Cattamanchi,R Destura
DOI: https://doi.org/10.5588/ijtldopen.24.0343
2024-10-01
Abstract:Background: Poor treatment outcomes among people with drug-resistant TB (DR-TB) are a major concern. Heteroresistance (presence of susceptible and resistant Mycobacterium tuberculosis in the same sample) has been identified in some people with TB, but its impact on treatment outcomes is unknown. Methods: We used targeted deep sequencing to identify mutations associated with DR-TB and heteroresistance in culture samples of 624 people with DR-TB. We evaluated the association between heteroresistance and time to unfavorable treatment outcome using Cox proportional hazards regression. Results: The proportion of drug-resistant isolates with a known mutation conferring resistance was lower for streptomycin (45.2%) and second-line injectables (79.1%) than for fluoroquinolones (86.7%), isoniazid (93.2%) and rifampin (96.5%). Fifty-two (8.3%) had heteroresistance, and it was more common for fluoroquinolones (4.6%) than rifampin (2.2%), second-line injectables (1.4%), streptomycin (1.7%), or isoniazid (1.3%). There was no association between heteroresistance and time to unfavorable outcome among people with multidrug-resistant TB (adjusted hazard ratio [aHR] 1.74, 95% CI 0.39-7.72) or pre-extensively DR-TB (aHR 0.65, 95% CI 0.24-1.72). Conclusions: Heteroresistance was relatively common (8.3%) among people with DR-TB in the Philippines. However, we found insufficient evidence to demonstrate an impact on unfavorable treatment outcomes.